Primary sclerosing cholangitis

Albireo to Participate in Jefferies London Healthcare Conference

Retrieved on: 
Wednesday, November 9, 2022

BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced participation in the Jefferies London Healthcare Conference in London, UK, from November 15-17, 2022.

Key Points: 
  • BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced participation in the Jefferies London Healthcare Conference in London, UK, from November 15-17, 2022.
  • Simon Harford, Chief Financial Officer of Albireo, will be presenting on November 15, 2022, at 10:20 AM GMT.
  • A replay of the webcast will be available on-demand on the Albireo Investors page: ir.albireopharma.com .
  • Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat pediatric and adult liver diseases.

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

Retrieved on: 
Tuesday, November 8, 2022

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported third quarter 2022 financial results.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported third quarter 2022 financial results.
  • A treatment effect was observed at all three doses tested on top of standard of care therapy and as monotherapy.
  • INTEGRIS-IPF Phase 2a trial of PLN-74809 (bexotegrast) at 320 mg on track for 12-week data readout in early first quarter 2023.
  • Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis.

Chemomab Presents Clinical Data from Investigator-Initiated Study Showing CM-101 Reduced Inflammatory and Fibrogenesis-Related Biomarkers in Patients with Severe Lung Injury Derived from Covid-19

Retrieved on: 
Wednesday, November 9, 2022

TEL AVIV, Israel, Nov. 9, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, announced that clinical data presented today showed that CM-101 was safe and well-tolerated and achieved reductions in biomarkers associated with lung inflammation and fibrogenesis in a clinical study in patients hospitalized with COVID-19-derived lung injury. CM-101 is a first-in-class monoclonal antibody that neutralizes CCL24, a soluble protein with pro-fibrotic and pro-inflammatory effects. It is in development for the treatment of fibro-inflammatory disorders, including primary sclerosingcholangitis (PSC) and systemic sclerosis (SSc).

Key Points: 
  • The presentation, Treatment with CM-101 Reduced Inflammatory & Fibrotic Biomarkers in Patients with COVID-19-Derived Lung Damage, was discussed by Chemomab co-founder and Chief Scientific Officer Dr. Adi Mor at the Union World Conference on Lung Health 2022.
  • The objective of the study was to evaluate the drug's safety and activity in hospitalized COVID-19 patients with severe pneumonia, including its impact on biomarkers related to lung inflammation that are also relevant in systemic sclerosis.
  • The open label, single arm trial enrolled 16 adult COVID-19 patients with severe respiratory involvement.
  • CM-101 exposures and target engagement profiles were similar to what Chemomab researchers have seen in previous clinical studies of CM-101.

Mirum Presents New Data from LIVMARLI Phase 3 PFIC Study and ALGS Infant Study in Late-Breaker Presentations at The Liver Meeting of AASLD

Retrieved on: 
Monday, November 7, 2022

The youngest ALGS patient in the study was two months of age, with an average age of seven months.

Key Points: 
  • The youngest ALGS patient in the study was two months of age, with an average age of seven months.
  • Based on the safety and tolerability data observed in RISE, LIVMARLI may be an effective treatment option for ALGS patients as young as two months of age.
  • The objective of the study was to report real-world safety observations for patients enrolled in the LIVMARLI global expanded access program.
  • LIVMARLI has received Breakthrough Therapy designation for ALGS and PFIC type 2 and orphan designation for ALGS, PFIC and biliary atresia.

Chemomab Presents Preclinical Data at AASLD The Liver Meeting® 2022 Highlighting Key Role of CCL24 in Pathophysiology of Primary Sclerosing Cholangitis

Retrieved on: 
Monday, November 7, 2022

TEL AVIV, Israel, Nov. 7, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced a poster presentation at The Liver Meeting® 2022, hosted by the American Association for the Study of Liver Diseases (AASLD), being held in Washington, D.C. November 4-8, 2022.

Key Points: 
  • Chemomab is currently assessing CM-101 in a Phase 2 clinical trial for the treatment of PSC.
  • Chemomab researchers used flow cytometry and single-cell RNA sequencing (scRNA-seq) methods to analyze immune cell trafficking in an animal model of PSC.
  • Furthermore, the studies showed that these effects are distinctive to CCL24 compared to CCL11, a member of a related pro-inflammatory cytokine family.
  • The Liver Meeting 2022 hosted by AASLD is the world's premier meeting on liver disease providing access to the most cutting-edge science in the field.

Mirum Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 9, 2022

Retrieved on: 
Tuesday, November 1, 2022

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report third quarter financial results on Wednesday, November 9, 2022.

Key Points: 
  • Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report third quarter financial results on Wednesday, November 9, 2022.
  • Mirum will host a conference call to discuss the third quarter financial results and recent corporate progress.
  • Mirum will be joined by guest speaker Richard J. Thompson, M.D., professor of molecular hepatology Kings College, London to discuss LIVMARLI and the results from the MARCH Phase 3 study.
  • Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases.

Chemomab Therapeutics to Report Third Quarter 2022 Financial Results and Provide a Business Update

Retrieved on: 
Tuesday, November 1, 2022

TEL AVIV, Israel, Nov. 1, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd .

Key Points: 
  • TEL AVIV, Israel, Nov. 1, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd .
  • (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the company will release its third quarter 2022 financial results and provide a business update on Friday, November 11, 2022 at 8:00 am Eastern Time.
  • During the event, Chemomab's management team will review third quarter 2022 performance, discuss recent and upcoming developments and conduct a live question-and-answer session.
  • Please call 5-10 minutes before the scheduled start time, enter the conference passcode and ask the operator for the Chemomab conference call.

Albireo to Report Q3 2022 Financial Results on November 8, 2022

Retrieved on: 
Monday, October 31, 2022

ET onNovember 8, 2022, to provide a business update and review the companys financial results for the quarter endedSeptember 30, 2022.

Key Points: 
  • ET onNovember 8, 2022, to provide a business update and review the companys financial results for the quarter endedSeptember 30, 2022.
  • To access the live conference call by phone, dial 1-855-327-6837(domestic) or 1-631-891-4304 (international), and provide the access code 10020423.
  • Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat pediatric and adult liver diseases.
  • Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden.

LISCure Biosciences Announces Oral Presentation of New Drug Candidate for NASH at Upcoming AASLD The Liver Meeting 2022

Retrieved on: 
Friday, October 28, 2022

SEOUL, South Korea, Oct. 28, 2022 /PRNewswire/ -- LISCure Biosciences, a clinical-stage biopharmaceutical company developing microbe-oriented new drugs based on innovative technologies, today announced that a new drug candidate for NASH was selected for an oral presentation at the American Association for The Study of Liver Diseases (AASLD) The Liver Meeting 2022, to be held November 4-8 in Washington DC. As part of the presentation, LISCure will become the first Korean biotech company accepted for an oral presentation at AASLD The Liver Meeting.

Key Points: 
  • As part of the presentation, LISCure will become the first Korean biotech company accepted for an oral presentation at AASLD The Liver Meeting.
  • Oral Presentation Date and Time: Monday, November 7, 2022, 4:30 PM
    AASLD is the leading global association in the liver disease field founded in 1950.
  • AASLD The Liver Meeting is an annual event in which more than 10,000 attendees - hepatologists, health professionals, and pharmaceutical industry - participate from around the world.
  • LISCure's new drug, a clinical-stage novel strain candidate, aims the "first-in-class" microbiome-based therapy for NASH and other liver diseases.

Chemomab Therapeutics to Present at Upcoming Scientific Conferences

Retrieved on: 
Friday, October 28, 2022

TEL AVIV, Israel, Oct. 28, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd .

Key Points: 
  • TEL AVIV, Israel, Oct. 28, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd .
  • (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the company will participate in several scientific conferences in November.
  • Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity.
  • CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.